Anaveon is a pre-clinical phase biopharmaceutical company that specialises in the development of treatments for diseases with immune system dysfunction.

Anaveon are exploiting the power of cytokines to orchestrate immune responses by using protein engineering to create safe and effective treatments for a variety of serious diseases. The first drug they are taking into clinical trials is a selective interleukin-2(IL-2) receptor agonist which is a fusion protein of a highly specific anti-IL-2 antibody and IL-2. They have shown that ANV419 can selectively promote the function of immune effector cells, making it a potential treatment for a range of cancer types. Anaveon are now ready to take ANV419 into clinical testing, bringing it a step closer to the patients who need it.

Their goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.